Market Overview

What To Do With Celgene Now With Major Catalysts Gone

Share:
What To Do With Celgene Now With Major Catalysts Gone

Celgene Corporation (NASDAQ: CELG)’s discontinuation of mongerson for Crohn’s disease is decidedly negative. The stock plunged 8.2 percent in premarket trading.

But the extent of justified pessimism depends on prior expectations.

UBS had long discounted mongerson’s prospects and, at its loss, maintains a Buy on the stock. But Citi’s faith was shaken.

“This removes a major upside catalyst in late 2018 as the street was skeptical about its opportunity, but it was part of our Buy thesis,” Citi analyst Robyn Karnauskas wrote in a Friday note.

Karnauskas downgraded Celgene to Neutral and lowered her price target to $140 (see Karnauskas' track record here).

Life Without Mongerson

The loss of mongerson places extra emphasis on upcoming phase 3 trials for luspatercept and ozanimod in ulcerative colitis. The two candidates face high Street expectations, with extra pressure on ozanimod for treatment of inflammatory bowel disease. Citi expects the latter’s results in either 2018 or 2019.

Their success is critical in countering the effects of impending competition to revlimid, which loses patent protection in 2021.

“Celgene is now a show me story,” Karnauskas wrote. “We acknowledge the company has LOTS of opportunity for upside from their broad pipeline. But many of their products are EARLY.”

At the time of publication, Celgene was set to open down 8 percent off Thursday’s closing rate of $135.96.

Related Link: 4 Biotech Stocks Initiated At A Buy: Acceleron, Tesaro, Mirati, Fate

Latest Ratings for CELG

DateFirmActionFromTo
Nov 2019Standpoint ResearchDowngradesBuyHold
Nov 2019BairdDowngradesOutperformNeutral
May 2019BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Downgrades Price Target Reiteration Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com